We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Protein Design Labs (PDL) and Biogen Idec have announced plans to collaborate on the joint development, manufacture and commercialization of three Phase II antibody products to treat various diseases such as multiple sclerosis and cancer.
Schering AG has signed a collaboration and licensing agreement with AstraZeneca that will focus on the development of selective glucocorticoid receptor agonists (SEGRAs), a new class of anti-inflammatory agents.
The Federal Trade Commission (FTC) has tentatively approved Novartis’ acquisition of U.S. generic firm Eon Labs on the condition that Novartis sells three drug products to a competitor.
It didn’t take long for Teva Pharmaceutical to return to its position as the world’s largest generic drugmaker. The Israeli company reclaimed the top spot with a splash, announcing plans July 25 to purchase U.S.-based Ivax — the world’s fourth largest generic firm — for $7.4 billion.
The Federal Trade Commission (FTC) has tentatively approved Novartis’ acquisition of U.S. generic firm Eon Labs on the condition that Novartis sells three drug products to a competitor.
Mylan Laboratories is seeking a licensee for its highly anticipated beta-blocker nebivolol and could select a partner as early as this fall, company officials said during a recent conference call.